Yarrow Bioscience, Inc. Common Stock (YARW) Stock Price
YARWStock
$39.25
Market Cap$104.79M
P/E—
PEG Ratio—
Div yield—
Beta—
YARW Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)37.77%
VGM Score5.21
YARW Earnings Surprise History
Q2 26-2.14est. —
YARW Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.90
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
YARWYarrow Bioscience, Inc. Common Stock | — | — | F | $39.25 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Yarrow Bioscience, Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.